危重成人患者游离丙戊酸不成比例升高的临床后果:多中心回顾性队列研究
这项多中心回顾性队列研究纳入两个学术医学中心2015年12月至2023年12月ICU中接受丙戊酸治疗并同时测量总浓度和游离浓度的成人患者311例,共550对浓度数据。结果显示,84%的样本存在游离丙戊酸不成比例升高;游离丙戊酸浓度每升高2.5 μg/mL,与血小板减少(aOR 1.15,95%CI 1.05-1.26)和肝毒性(aOR 1.11,95%CI 1.05-1.18)独立相关。白蛋白浓度(aOR 0.17,95%CI 0.08-0.36)、血尿素氮(aOR 1.36,95%CI 1.09-1.70)和丙泊酚暴露(aOR 3.06,95%CI 1.38-6.79)与游离丙戊酸不成比例升高相关。作者认为,危重患者应直接测量游离丙戊酸浓度,因为总浓度会低估游离浓度;大多数危重患者存在风险,尤其是低白蛋白血症、尿毒症和丙泊酚暴露者。
要点
- 危重成人中84%(462/550)的丙戊酸浓度样本存在游离丙戊酸不成比例升高,总浓度不能可靠反映游离浓度。
- 游离丙戊酸浓度每升高2.5 μg/mL,血小板减少风险增加(aOR 1.15,95%CI 1.05-1.26),肝毒性风险增加(aOR 1.11,95%CI 1.05-1.18)。
- 白蛋白浓度越高,游离丙戊酸不成比例升高风险越低(aOR 0.17,95%CI 0.08-0.36);血尿素氮越高(aOR 1.36,95%CI 1.09-1.70)和丙泊酚暴露(aOR 3.06,95%CI 1.38-6.79)风险越高。
- 作者认为,危重患者应直接测量游离丙戊酸浓度,尤其对低白蛋白血症、尿毒症和丙泊酚暴露者。
适用人群与场景
- 两个学术医学中心ICU收治的成人患者,接受丙戊酸治疗并同时测量总丙戊酸和游离丙戊酸浓度。
- 纳入时间为2015年12月至2023年12月。
诊断标准与关键阈值
- 不成比例游离丙戊酸升高的定义:游离丙戊酸浓度高于预期且与总浓度不成比例,例如游离丙戊酸高于参考范围而总丙戊酸低于参考范围。
研究设计与关键结果
- 多中心回顾性观察性队列研究,纳入311例患者(平均年龄58岁,标准差±17岁;女性36%;非白人31%;29%入院前已使用丙戊酸),共550对同时测量的游离和总丙戊酸浓度。
- 总丙戊酸浓度中位数46 μg/mL(四分位距34-63),游离丙戊酸浓度中位数17 μg/mL(四分位距11-23),游离分数中位数35%(四分位距25-63%)。
- 462份(84%)样本存在游离丙戊酸不成比例升高。
- 游离丙戊酸浓度每升高2.5 μg/mL与血小板减少独立相关(校正比值比1.15,95%置信区间1.05-1.26),与肝毒性独立相关(校正比值比1.11,95%置信区间1.05-1.18)。
- 白蛋白浓度(校正比值比0.17,95%置信区间0.08-0.36)、血尿素氮(校正比值比1.36,95%置信区间1.09-1.70)和丙泊酚暴露(校正比值比3.06,95%置信区间1.38-6.79)与游离丙戊酸不成比例升高相关。
证据类型、等级与局限
- 证据类型:多中心回顾性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,危重患者应直接测量游离丙戊酸浓度,因为总丙戊酸浓度会低估游离浓度。
- 作者认为,大多数危重患者存在游离丙戊酸不成比例升高的风险,尤其是低白蛋白血症、尿毒症和丙泊酚暴露者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Valproate has a narrow therapeutic index and unpredictable protein binding, and critically ill patients may experience unexpectedly elevated free concentrations. We sought to identify the clinical consequences and determinants of disproportionate free valproate concentration elevation in critically ill adults.
METHODS: This was a retrospective observational cohort study conducted at two academic medical centers from December 2015 to December 2023. Adult patients admitted to an intensive care unit who were receiving valproate and had concurrent total and free valproate concentrations measured were eligible for inclusion. We examined whether valproate concentrations were independently associated with adverse effects (AEs), including thrombocytopenia, hepatotoxicity, hyperammonemia, and pancreatic injury. Secondarily, determinants of disproportionate free valproate elevation, defined as a free valproate concentration that was greater than expected and out of proportion to the total concentration (e.g., free valproate above reference range but total valproate below reference range), were also identified.
RESULTS: A total of 311 patients (mean age 58 [SD ± 17] years, 36% female, 31% non-White, and 29% on valproate prior to admission) with 550 concurrent free valproate and total valproate pairs were included. The median total valproate concentration was 46 μg/mL (interquartile range [IQR] 34-63), and the median free valproate concentration was 17 μg/mL (IQR 11-23); the median free fraction was 35% (IQR 25-63%). Disproportionate free valproate elevation was observed in 462 (84%) samples. Each 2.5-μg/mL increase in free valproate concentration was associated with thrombocytopenia (adjusted odds ratio [aOR] 1.15, 95% confidence interval [CI] 1.05-1.26) and hepatotoxicity (aOR 1.11, 95% CI 1.05-1.18). Albumin concentration (aOR 0.17, 95% CI 0.08-0.36), blood urea nitrogen (aOR 1.36, 95% CI 1.09-1.70), and propofol exposure (aOR 3.06, 95% CI 1.38-6.79) were associated with disproportionate free valproate elevation.
CONCLUSIONS: Elevated free valproate concentrations were associated with hepatotoxicity and thrombocytopenia; free valproate concentrations should be directly measured in critically ill patients because it is underrepresented by total valproate. Most critically ill patients are at risk, especially those with hypoalbuminemia, uremia, and propofol exposure.
参考来源
- Webb AJ, Gagnon DJ, Brown CS, et al. Clinical Consequences of Disproportionate Free Valproate Elevation in Critically Ill Adult Patients: A Multicenter Retrospective Cohort Study. Neurocrit Care. 2025. PMID: 40133756. doi:10.1007/s12028-025-02243-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。